ArticleClinical, cosmetic and investigational dermatology2026
Global, Regional, and National Burden of Alopecia Areata in Children and Adolescents Aged 0-19 years from 1990 to 2021 and Projection to 2040.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Case Report: Vitiligo and Alopecia Universalis Following Rituximab Therapy in a Patient with Myasthenia Gravis.Clinical, cosmetic and investigational dermatology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Global epidemiological patterns of alopecia areata in pediatric populations remain inadequately characterized. We evaluated the disease burden and trends among children and adolescents aged 0-19 years across 204 countries and territories from 1990 to 2021 and projected the disease development from 2022 to 2040. Methods: Using Global Burden of Disease (GBD) 2021 data, we analyzed incidence, prevalence, and disability-adjusted life years (DALYs), stratified by sex, age, and Sociodemographic Index (SDI). Temporal trends were quantified via estimated annual percentage changes (EAPC) in age-standardized rates. The Bayesian age cohort model was used to predict prevalent cases trend from 2022 to 2040. Results: In 2021, global prevalent cases increased by 15.79% (1990-2021), yet age-standardized incidence (ASIR), prevalence (ASPR), and DALY rates (ASDR) declined significantly (EAPC range: -0.092 to -0.099). Females consistently bore 75% higher burden than males. Disease metrics escalated with age, peaking in the 15-19 age subgroup. Low-SDI group exhibited rising ASIR/ASPR/ASDR (EAPC up to 0.050), contrasting declines in higher-SDI areas. High-income North America recorded the highest ASPR (145.84/100,000) but the most rapidly decline (EAPC=-0.251), while Central Sub-Saharan Africa showed the steepest increases. India reported the highest national prevalent cases (420,913) in 2021. The disease burden of alopecia areata among children and adolescents aged 0-19 years worldwide and in India will tend to be stable from 2022 to 2040, while the disease burden in China will rise, and in the United States of America, it will continue to decline. Conclusion: Despite a decrease in the relative burden, the absolute number of alopecia areata cases rose globally. Critical disparities persist among females, adolescents (15-19 years), and low-SDI populations-particularly in Central Sub-Saharan Africa. Targeted interventions for these vulnerable groups are urgently needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.